Altru Health System has entered a strategic alliance to adopt Deep Lens’ artificial-intelligence (AI)-based clinical trial matching solution, named VIPER, across its network.
VIPER leverages cloud-based technology to facilitate, triage and fast-track the patient enrolment during the clinical trial recruitment process.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It is developed to improve efficiencies using automated screening and data management. With the solution, Altru expects more opportunities to take part in new precision medicine trials.
Altru Health System Research Program supervisor Ashlee Dagoberg said: “VIPER will not only assist in expanding patient access to trials, but the relationship with Deep Lens will allow us to broaden our clinical research programme.
“They will bring new sponsored trials to our system which in turn will allow our patients to participate in more precision medicine studies involving emerging new therapies.”
VIPER will be deployed directly into the Altru Health System’s electronic medical record EPIC and molecular data feeds – Foundation Medicine, Myriad Genetics, Tempus, Guardant360.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe AI solution will also be integrated into the company’s pathology system EPIC Beaker. With VIPER, Altru aims to automatically detect eligible patients for clinical trials.
Altru expects that deploying VIPER into its network will enable all cancer patients across its network in various geographical areas to access any clinical trial for which they may be qualified.
Approximately more than 15,000 oncology trials are actively enrolling subjects, but participation is often as low as 3%, Altru noted.
Patient recruitment challenges such as limited trial site capacity and narrow study eligibility requirements have been identified. However, the participation rate in cancer trials has not improved significantly over time.
To help improve participation, VIPER automates the trial screening process and matches patients at the time of diagnosis to suitable trials. The solution incorporates and analyses tailored genomic data, electronic medical records and pathology data.
Last month, Oregon Oncology Specialists agreed to integrate a Deep Lens’ AI-based clinical trial screening platform.
